Literature DB >> 22930623

Update on role of chemotherapy in head and neck squamous cell cancer.

S Marur1, A A Forastiere.   

Abstract

Head and neck squamous cell cancer (HNSCC) is most commonly a tobacco-related disease, affecting nearly 600,000 people worldwide each year. For decades, HNSCC has been treated successfully with multimodality treatments including, surgery, radiation, and chemotherapy, though the 'perfect' treatment paradigm remains elusive. This review will discuss a number of clinical trials, comparing various combinations of chemotherapy and the settings in which they are most successful. Promising research and recent data on the combination of cytotoxic chemotherapy with new biological agents indicate chemotherapy plays a critical role in treatment of HNSCC and will only continue to improve.

Entities:  

Keywords:  Head and neck cancer; cetuximab; chemoradiation; chemotherapy; induction chemotherapy; targeted therapy

Year:  2010        PMID: 22930623      PMCID: PMC3421005          DOI: 10.1007/s13193-010-0021-y

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  69 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Authors:  A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

3.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

4.  High association of human papillomavirus infection with oral cancer: a case-control study.

Authors:  Gabriela Anaya-Saavedra; Velia Ramírez-Amador; Ma Esther Irigoyen-Camacho; Claudia Ma García-Cuellar; Miriam Guido-Jiménez; Rocío Méndez-Martínez; Alejandro García-Carrancá
Journal:  Arch Med Res       Date:  2007-11-08       Impact factor: 2.235

5.  Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

Authors:  Ezra E W Cohen; Darren W Davis; Theodore G Karrison; Tanguy Y Seiwert; Stuart J Wong; Sreenivasa Nattam; Mark F Kozloff; Joseph I Clark; Duen-Hwa Yan; Wen Liu; Carolyn Pierce; Janet E Dancey; Kerstin Stenson; Elizabeth Blair; Allison Dekker; Everett E Vokes
Journal:  Lancet Oncol       Date:  2009-02-07       Impact factor: 41.316

6.  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

Authors:  C Jacobs; G Lyman; E Velez-García; K S Sridhar; W Knight; H Hochster; L T Goodnough; J E Mortimer; L H Einhorn; L Schacter
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

7.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Authors:  Denis Soulieres; Neil N Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

8.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

9.  Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.

Authors:  R Hitt; A Jimeno; M Rodríguez-Pinilla; J L Rodríguez-Peralto; J M Millán; A López-Martín; A Brandariz; C Peña; H Cortés-Funes
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

10.  Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).

Authors:  C Domenge; C Hill; J L Lefebvre; D De Raucourt; B Rhein; P Wibault; P Marandas; B Coche-Dequeant; M Stromboni-Luboinski; H Sancho-Garnier; B Luboinski
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more
  4 in total

1.  The chemopreventive and clinically used agent curcumin sensitizes HPV (-) but not HPV (+) HNSCC to ionizing radiation, in vitro and in a mouse orthotopic model.

Authors:  Stephen Tuttle; Lauren Hertan; Natalie Daurio; Sarah Porter; Charanya Kaushick; Daqing Li; Shunsuke Myamoto; Alex Lin; Bert W O'Malley; Constantinos Koumenis
Journal:  Cancer Biol Ther       Date:  2012-05-01       Impact factor: 4.742

2.  Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.

Authors:  Carolina Nör; Zhaocheng Zhang; Kristy A Warner; Lisiane Bernardi; Fernanda Visioli; Joseph I Helman; Rafael Roesler; Jacques E Nör
Journal:  Neoplasia       Date:  2014-02       Impact factor: 5.715

3.  Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence.

Authors:  Sundaram Subramanian; Nithya Sridharan; V Balasundaram; Sameer Chaudhari
Journal:  South Asian J Cancer       Date:  2018 Jul-Sep

4.  Therapeutic implications of tumor free margins in head and neck squamous cell carcinoma.

Authors:  Clara Backes; Henning Bier; Andreas Knopf
Journal:  Oncotarget       Date:  2017-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.